Ceftazidime Sodium + Tazobactam SodiumThird Party Manufacturing in India

Ceftazidime Sodium + Tazobactam Sodium works by combining a broad-spectrum cephalosporin antibiotic with a beta-lactamase inhibitor to combat bacterial resistance. Ceftazidime sodium targets bacterial cell wall synthesis. It binds to penicillin-binding proteins in the bacterial membrane, blocking transpeptidation enzymes that build the peptidoglycan cell wall structure. This leads to osmotic instability, cell lysis, and bacterial cell death. To protect this antibiotic from inactivation by resistant bacteria, tazobactam sodium is added. Tazobactam is a penicillin sulfone beta-lactamase inhibitor that binds irreversibly to plasmid-mediated and chromosomal beta-lactamases produced by resistant pathogens. By neutralizing these enzymes, tazobactam prevents the hydrolysis of the beta-lactam ring in ceftazidime. This synergistic combination restores the activity of ceftazidime against beta-lactamase-producing enterobacteria and Pseudomonas strains. The formulation provides a powerful, sterile parenteral treatment option for severe nosocomial infections. It allows clinicians to treat complex, drug-resistant infections while reducing the need for reserve carbapenem therapies. The combination has excellent tissue penetration, particularly in pulmonary and abdominal tissues.

Therapeutic Uses

Ceftazidime Sodium + Tazobactam Sodium is prescribed for the treatment of:

• Nosocomial Pneumonia: Indicated for hospital-acquired and ventilator-associated pneumonia caused by resistant strains.
• Complicated Intra-abdominal Infections: Treats deep abdominal abscesses, peritonitis, and biliary tract infections.
• Complicated Urinary Tract Infections: Prescribed for treatment-resistant pyelonephritis and urinary sepsis.
• Skin and Soft Tissue Infections: Treats severe diabetic foot infections, post-surgical wounds, and cellulitis.
• Septicemia: Used as an empirical or targeted treatment for bloodstream infections.
• Empirical Therapy in Neutropenia: Treats suspected infections in immunocompromised cancer patients.

Why Manufacturers Choose Ceftazidime Sodium + Tazobactam Sodium

Ceftazidime Sodium + Tazobactam Sodium is a high-value combination antibiotic in the B2B pharmaceutical sector. With the global challenge of antimicrobial resistance, particularly from ESBL-producing bacteria, this combination has seen a rapid increase in hospital prescriptions. Sourcing it from WHO-GMP certified facilities in India allows international buyers to access cost-effective, high-quality injectables. For manufacturers, it offers excellent commercial margins and positions them as providers of advanced antibiotic therapies. The sterile dry powder formulation requires specialized manufacturing lines, ensuring less competition in the marketplace. This makes Ceftazidime Sodium + Tazobactam Sodium one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.